Literature DB >> 12030260

Where does parkinson disease pathology begin in the brain?

Kelly Del Tredici1, Udo Rüb, Rob A I De Vos, Jürgen R E Bohl, Heiko Braak.   

Abstract

The substantia nigra is not the induction site in the brain of the neurodegenerative process underlying Parkinson disease (PD). Instead, the results of this semi-quantitative study of 30 autopsy cases with incidental Lewy body pathology indicate that PD in the brain commences with the formation of the very first immunoreactive Lewy neurites and Lewy bodies in non-catecholaminergic neurons of the dorsal glossopharyngeus-vagus complex, in projection neurons of the intermediate reticular zone, and in specific nerve cell types of the gain setting system (coeruleus-subcoeruleus complex, caudal raphe nuclei, gigantocellular reticular nucleus), olfactory bulb, olfactory tract, and/or anterior olfactory nucleus in the absence of nigral involvement. The topographical parcellation of the nuclear grays described here is based upon known architectonic analyses of the human brainstem and takes into consideration the pigmentation properties of a few highly susceptible nerve cell types involved in PD. In this sample and in all 58 age- and gender-matched controls, Lewy bodies and Lewy neurites do not occur in any of the known prosencephalic predilection sites (i.e. hippocampal formation, temporal mesocortex, proneocortical cingulate areas, amygdala, basal nucleus of Meynert, interstitial nucleus of the diagonal band of Broca, hypothalamic tuberomamillary nucleus).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030260     DOI: 10.1093/jnen/61.5.413

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  200 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

Authors:  Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

2.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

Review 3.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

4.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

Review 5.  The bowel and beyond: the enteric nervous system in neurological disorders.

Authors:  Meenakshi Rao; Michael D Gershon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-07-20       Impact factor: 46.802

Review 6.  Gut dysfunction in Parkinson's disease.

Authors:  Adreesh Mukherjee; Atanu Biswas; Shyamal Kumar Das
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

7.  Advanced time-series analysis of MEG data as a method to explore olfactory function in healthy controls and Parkinson's disease patients.

Authors:  Sanne Boesveldt; Cornelis J Stam; Dirk L Knol; Jeroen P A Verbunt; Henk W Berendse
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

Review 8.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 9.  The pathology roadmap in Parkinson disease.

Authors:  D James Surmeier; David Sulzer
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

Review 10.  Electrical stimulation of cranial nerves in cognition and disease.

Authors:  Devin Adair; Dennis Truong; Zeinab Esmaeilpour; Nigel Gebodh; Helen Borges; Libby Ho; J Douglas Bremner; Bashar W Badran; Vitaly Napadow; Vincent P Clark; Marom Bikson
Journal:  Brain Stimul       Date:  2020-02-23       Impact factor: 8.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.